Schrödinger, Inc. (SDGR)
Market Cap | 1.30B |
Revenue (ttm) | 200.63M |
Net Income (ttm) | -201.47M |
Shares Out | 72.80M |
EPS (ttm) | -2.79 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 605,447 |
Open | 17.53 |
Previous Close | 17.80 |
Day's Range | 17.51 - 17.97 |
52-Week Range | 16.67 - 38.00 |
Beta | 1.50 |
Analysts | Buy |
Price Target | 32.60 (+81.92%) |
Earnings Date | Oct 30, 2024 |
About SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serv... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is $32.6, which is an increase of 81.92% from the latest price.
News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on Octobe...
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company's PRMT5-MTA inhibitor program, wil...
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
NEW YORK , Sept. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Schrodinger, Inc. (NASDAQ: SDGR) breached their...
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy...
Schrödinger Reports Strong Second Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the second quarter of 2024.
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close.
Schrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For Free
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better dru...
Schrödinger to Present at Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.
Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therape...
Schrödinger Reports First Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the first quarter of 2024.
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close.
Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the fourth quarter and full-year and provided its financial outlook for 2024.
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024.
Schrodinger: Attractive Risk-Reward
Customers in the biopharma industry are cutting spending, creating a soft demand environment for Schrodinger's software and drug discovery services. Despite the recent share price spike, Schrodinger's...
Schrödinger, Inc. (SDGR) Q3 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Commun...
Schrödinger Reports Third Quarter 2023 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial res...
Schrödinger to Announce Third Quarter 2023 Financial Results on November 1
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will report third quarter 2023 financial results on November 1, 2023.
Schrodinger: Leading The AI Healthcare Revolution
Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary s...
The Good And Bad: Allison Transmission & Schrodinger Inc.
See two of the featured stocks from this month's model portfolios.
Schrodinger: More Than An AI Bubble Stock
Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight finan...
Schrödinger, Inc. (SDGR) Q2 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Ak...
Schrödinger Reports Second Quarter 2023 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended on June 30, 2023.
Biotech Stocks Join AI-Fueled Rally
Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.
Schrödinger to Announce Second Quarter 2023 Financial Results on August 2
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023...